Addex Therapeutics (ADXN) Return on Capital Employed (2022 - 2025)
Historic Return on Capital Employed for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to 0.68%.
- Addex Therapeutics' Return on Capital Employed fell 3000.0% to 0.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.68%, marking a year-over-year decrease of 3000.0%. This contributed to the annual value of 0.4% for FY2024, which is 2700.0% up from last year.
- Latest data reveals that Addex Therapeutics reported Return on Capital Employed of 0.68% as of Q3 2025, which was down 3000.0% from 0.6% recorded in Q2 2025.
- Addex Therapeutics' Return on Capital Employed's 5-year high stood at 5.86% during Q1 2024, with a 5-year trough of 6.96% in Q1 2023.
- In the last 4 years, Addex Therapeutics' Return on Capital Employed had a median value of 0.65% in 2024 and averaged 1.62%.
- As far as peak fluctuations go, Addex Therapeutics' Return on Capital Employed skyrocketed by 128200bps in 2024, and later crashed by -64100bps in 2025.
- Addex Therapeutics' Return on Capital Employed (Quarter) stood at 5.42% in 2022, then surged by 73bps to 1.49% in 2023, then soared by 68bps to 0.47% in 2024, then tumbled by -43bps to 0.68% in 2025.
- Its Return on Capital Employed stands at 0.68% for Q3 2025, versus 0.6% for Q2 2025 and 0.54% for Q1 2025.